Cardiosense Market Research Report
Company Overview
- Name: Cardiosense, Inc.
- Mission: Cardiosense aims to build a digital biomarker platform leveraging novel, multi-sensor devices and proprietary algorithms to detect early signs of disease and guide personalized therapy.
- Founded: No information is available.
- Key People: Omer Inan, Co-Founder and Chief Scientific Officer; Amit Gupta, Founder and CEO.
- Headquarters: 1375 W Fulton St Suite 650, Chicago, Illinois 60607, United States.
- Number of Employees: 11-50 employees.
- Revenue: No information is available.
- Known For: Developing a physiological waveform data platform to create predictive biomarkers for pre-symptomatic disease detection, focusing on cardiac health.
Products
1. CardioTag Sensor
- Description: Medical-grade, multi-sensor wearable device enabling wireless patient monitoring both in-hospital and at home.
- Key Features:
- Multi-sensor capability
- Wireless monitoring
2. Wavesense Platform
- Description: A device-agnostic software platform that aggregates, transmits, and analyzes physiological sensor data.
- Key Features:
- Compatibility with various devices
- Robust data analytics capabilities
3. Clinical AI
- Description: Digital biomarkers developed to detect early cardiac diseases by applying deep learning to physiological waveform data.
- Key Features:
- Integration of AI for early detection
- Personalized therapy guidance
Recent Developments
- Clinical Studies:
- Presented interim clinical study data for a machine learning algorithm aimed at heart failure management at the TCT 2024 Scientific Symposium.
- Recognition:
- CardioTag was named "Best IoT Healthcare Wearable Device" at the 2024 MedTech Breakthrough Awards.
- Research Initiatives:
- Commenced enrollment in a nationwide heart failure study in October 2023.
- Funding:
- Completed a $15.1 Million Series A financing round in December 2022 to advance their AI platform for heart disease.
- FDA Designation:
- Received FDA Breakthrough Device designation in February 2022 for an algorithm identifying patients at risk of decompensated heart failure.
- Partnerships:
- No new partnerships reported.
This report has been compiled using the available data up to 2024. For further updates or detailed financial information, please refer to future publications or the company's press releases.
